PSMA Ligand-Linker Conjugates for Selective Prostate Cancer Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer often have significant side effects due to non-specific targeting, affecting quality of life, and there is a need for more selective therapies that can target prostate-specific membrane antigen (PSMA) to minimize damage to non-target tissues.
Innovation Solution
Conjugates of biologically active agents linked to PSMA binding ligands through linkers of predetermined length and diameter, allowing for selective delivery to prostate cancer cells, including therapeutic, diagnostic, and imaging agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment methods (hormonal therapy, radiation therapy, surgery, chemotherapy) are used for prostate cancer, then cancer treatment efficacy is achieved, but significant side effects occur in non-target tissues (bones, liver) affecting quality of life
Solution Approach 1:
The patent uses PSMA-binding ligands as intermediary molecules that mediate the delivery of biologically active agents to prostate cancer cells. The ligand acts as a carrier that specifically targets PSMA on cancer cell surfaces, ensuring the therapeutic agent is delivered only to the intended target tissue rather than distributing systemically throughout the body, thus eliminating harmful side effects on non-target organs.
Solution Approach 2:
The invention implements local quality by creating conjugates with specific spatial and chemical properties that enable selective accumulation in prostate cancer tissues. The linker structure and ligand characteristics are designed to provide localized binding affinity and internalization characteristics that are unique to PSMA-expressing cells, allowing the therapeutic effect to be concentrated only where needed.
2Reliability
If PSMA binding ligands are used to target prostate cancer cells, then treatment specificity is improved, but the complexity of conjugate design and linker selection increases
Solution Approach 1:
The patent applies parameter changes by systematically varying linker characteristics (length, diameter, functional groups) to optimize conjugate performance. By adjusting these physical and chemical parameters, the invention achieves the desired balance between binding affinity, cellular internalization efficiency, and therapeutic efficacy, transforming a complex design problem into a systematic parameter optimization process.
Solution Approach 2:
The conjugate molecule is segmented into distinct functional components: the PSMA-binding ligand portion, the linker portion, and the biologically active agent portion. This segmentation allows each component to be independently designed, synthesized, and optimized for its specific function, reducing the overall complexity of the conjugate design process while maintaining high treatment specificity.
3Measurement precision
If linkers of predetermined length and diameter are used, then delivery precision to prostate cancer cells is enhanced, but the number of possible linker configurations increases
Solution Approach 1:
The patent applies local quality by specifying precise geometric parameters (length and diameter) for the linker portion of the conjugate. These localized dimensional constraints ensure optimal spatial fit within the PSMA binding site and proper orientation for internalization, achieving high delivery precision through controlled local geometry rather than requiring complex overall molecular configurations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates effectively target prostate cancer cells, reducing side effects by enhancing specificity and efficacy in treatment and imaging while minimizing impact on other tissues.
Implementation Method 1
PSMA binding ligands that bind to prostate specific membrane antigen (PSMA)
Implementation Method 2
PSMA is internalized in a process analogous to endocytosis observed with cell surface receptors, such as vitamin receptors
Data Source
AI summary
Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.